Polar Asset Management Partners Inc. Makes New $3.70 Million Investment in DexCom, Inc. (NASDAQ:DXCM)

Polar Asset Management Partners Inc. acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 47,564 shares of the medical device company's stock, valued at approximately $3,699,000.

Several other large investors have also made changes to their positions in DXCM. Private Trust Co. NA lifted its position in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Optiver Holding B.V. acquired a new position in shares of DexCom during the 4th quarter worth about $33,000. TD Private Client Wealth LLC lifted its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC lifted its position in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom during the 4th quarter worth about $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Price Performance

Shares of NASDAQ DXCM traded up $1.10 during mid-day trading on Friday, hitting $85.96. 4,257,051 shares of the stock were exchanged, compared to its average volume of 4,370,190. The company has a market cap of $33.71 billion, a P/E ratio of 60.11, a PEG ratio of 2.30 and a beta of 1.43. The stock's fifty day simple moving average is $74.67 and its two-hundred day simple moving average is $78.65. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $121.47.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business's quarterly revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.32 EPS. As a group, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on DXCM shares. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Cfra Research upgraded DexCom to a "hold" rating in a research note on Friday, March 21st. Piper Sandler reduced their target price on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Barclays lifted their price target on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Finally, Morgan Stanley increased their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $98.32.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president now owns 109,621 shares of the company's stock, valued at $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the sale, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This represents a 8.03% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 83,110 shares of company stock valued at $6,103,505. Corporate insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.